Diltiazem hydrochloride sustained release tablets and preparation method thereof

A technology of diltiazem hydrochloride and sustained-release tablets, which can be applied to medical formulas, medical preparations containing no active ingredients, medical preparations containing active ingredients, etc., and can solve problems such as organ dysfunction and increased risk of cardiovascular and cerebrovascular diseases. Achieve the effects of reducing vascular resistance, relieving exertional angina, and slowing down the heart rate

Inactive Publication Date: 2015-02-18
HARBIN SHENGJI PHARMA
View PDF2 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009]3. Irregular diet: especially overeating, which increases the risk of cardiovascular and cerebrovascular diseases
[0010]4. Like smoking and drinking: These two bad living habits can easily damage organs, hinder blood circulation, and further induce cardiovascular

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Diltiazem hydrochloride sustained release tablets and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0037] A diltiazem hydrochloride sustained-release tablet and a preparation method thereof, which are made of diltiazem hydrochloride, a sustained-release framework material, and a lubricant, wherein, in parts by weight, 60 parts of diltiazem hydrochloride, 50-150 parts of a sustained-release framework material, and 5 parts of a lubricant -25 servings.

[0038] According to optimal parts by weight, there are 60 parts of diltiazem hydrochloride, 125 parts of slow-release matrix material and 15 parts of lubricant.

[0039] The sustained-release matrix material is hypromellose.

[0040] The hypromellose is one or a mixture of 75hd100cr hypromellose, 75hd4000cr hypromellose, 75hd15000cr hypromellose, 100000cr hypromellose.

[0041] Described lubricant is magnesium stearate, talcum powder, silicon dioxide or a mixture of both.

Embodiment 2

[0043] A diltiazem hydrochloride sustained-release tablet and a preparation method thereof, the specific steps of the preparation method are:

[0044] Step 1, material preparation: pulverize diltiazem hydrochloride with a pulverizer, pass through a 100-mesh sieve, and set aside;

[0045] Step 2: Total mixing: weigh diltiazem hydrochloride and hypromellose in a three-dimensional mixer according to parts by weight and mix for 30 minutes, then take them out for later use;

[0046] Step 3: Granulation: Put the mixed fine powder of raw and auxiliary materials into the wet granulator, use pure water as the binder, put the binder into the liquid supply tank, turn on the machine, adjust the parameters, and start adding the moistening Wet agent, open the shearing flying knife at the same time, 2-5 minutes, discharge, use a swing granulator, granulate with a 20-mesh nylon screen, dry with a fluidized bed dryer, first dry with cool wind, wait After the skin is completely dry, turn on th...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides diltiazem hydrochloride sustained release tablets. The diltiazem hydrochloride sustained release tablets are prepared from 60 parts of diltiazem hydrochloride, 50-150 parts of sustained release skeleton material and 5-25 parts of lubricating agent by weight. A preparation method of the diltiazem hydrochloride sustained release tablets comprises the steps of material preparing, blending, granulating, blending, tabletting and aluminium-plastic packaging. The diltiazem hydrochloride sustained release tablets and the preparation method have the beneficial effects that the effects of dilating blood vessels, improving myocardial ischemia and reducing blood pressure are achieved by inhibiting internal flow of calcium ions towards coronary vessels and the surroundings of the coronary vessels or peripheral vascular smooth muscle cells; the diltiazem hydrochloride sustained release tablets have the advantages of good medicine stability, convenience in packaging, transportation and storage, and the like; the preparation method is simple and practicable and is suitable for industrial production.

Description

technical field [0001] The invention belongs to the technical field of chemical drug sustained-release preparations, in particular to a diltiazem hydrochloride sustained-release tablet and a preparation method thereof. Background technique [0002] Cardiovascular disease, also known as circulatory system disease, is a series of diseases involving the circulatory system. The circulatory system refers to the organs and tissues that transport blood in the human body, mainly including the heart, blood vessels (arteries, veins, capillaries), and can be subdivided into acute And chronic, generally related to arteriosclerosis. These diseases all have similar etiology, pathogenesis and treatment methods. [0003] Angina pectoris is a clinical syndrome caused by coronary insufficiency, myocardial acute, temporary ischemia and hypoxia. It is characterized by paroxysmal chest squeezing pain, which may be accompanied by other symptoms. The pain is mainly located at the back of the ste...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K9/22A61K31/554A61K47/38A61P9/10A61P9/12A61J3/10
Inventor 马玉国
Owner HARBIN SHENGJI PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap